- Home
- BMRN vs CPB Comparison
BMRN vs CPB Comparison
Compare BMRN & CPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMRN
- CPB
- Stock Information
- Founded
- BMRN 1996
- CPB 1869
- Country
- BMRN United States
- CPB United States
- Employees
- BMRN N/A
- CPB N/A
- Industry
- BMRN Biotechnology: Pharmaceutical Preparations
- CPB Packaged Foods
- Sector
- BMRN Health Care
- CPB Consumer Staples
- Exchange
- BMRN Nasdaq
- CPB Nasdaq
- Market Cap
- BMRN 10.0B
- CPB 9.2B
- IPO Year
- BMRN 1999
- CPB N/A
- Fundamental
- Price
- BMRN $52.00
- CPB $30.09
- Analyst Decision
- BMRN Buy
- CPB Hold
- Analyst Count
- BMRN 19
- CPB 16
- Target Price
- BMRN $90.89
- CPB $34.20
- AVG Volume (30 Days)
- BMRN 2.8M
- CPB 4.9M
- Earning Date
- BMRN 10-27-2025
- CPB 12-02-2025
- Dividend Yield
- BMRN N/A
- CPB 5.26%
- EPS Growth
- BMRN 59.53
- CPB 6.35
- EPS
- BMRN 2.68
- CPB 2.01
- Revenue
- BMRN $3,094,001,000.00
- CPB $10,253,000,000.00
- Revenue This Year
- BMRN $13.32
- CPB N/A
- Revenue Next Year
- BMRN $7.51
- CPB $1.15
- P/E Ratio
- BMRN $19.59
- CPB $14.75
- Revenue Growth
- BMRN 12.39
- CPB 6.40
- 52 Week Low
- BMRN $51.00
- CPB $29.39
- 52 Week High
- BMRN $73.51
- CPB $47.25
- Technical
- Relative Strength Index (RSI)
- BMRN 42.64
- CPB 40.38
- Support Level
- BMRN $51.80
- CPB $29.61
- Resistance Level
- BMRN $54.25
- CPB $30.29
- Average True Range (ATR)
- BMRN 1.73
- CPB 0.53
- MACD
- BMRN -0.03
- CPB -0.04
- Stochastic Oscillator
- BMRN 18.34
- CPB 15.80
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
About CPB Campbell Soup Company
Over the past 150-plus years, Campbell's has evolved into a leading domestic packaged food manufacturer, with a portfolio that extends beyond its iconic red-and-white labeled canned soup. In fiscal 2024 (July year-end), snacks accounted for nearly half of its revenue, followed by soup (28%), other simple meals (17%), and beverages (7%). Outside its namesake, its brands include Pepperidge Farm, Goldfish, Snyder's of Hanover, Swanson, Pacific Foods, Prego, Pace, V8, and recently acquired Rao's (a deal that closed in March 2024). Around 90% of its revenue results from the US and the remainder from Canada and Latin America.